Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase NA 1

Status

Unknown 15Completed 13Recruiting 10Active not recruiting 5Terminated 4Withdrawn 3Suspended 1Not yet recruiting 1Enrolling by invitation 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Breast Neoplasms 438Neoplasms 322Carcinoma, Non-Small-Cell Lung 250Prostatic Neoplasms 240Lung Neoplasms 176Colorectal Neoplasms 158Pancreatic Neoplasms 148Neoplasm Metastasis 142Leukemia, Myeloid, Acute 140Multiple Myeloma 131Lymphoma 128Carcinoma, Hepatocellular 127Ovarian Neoplasms 109Melanoma 109Head and Neck Neoplasms 101Brain Neoplasms 101Recurrence 100Leukemia 97Leukemia, Lymphocytic, Chronic, B-Cell 96Precursor Cell Lymphoblastic Leukemia-Lymphoma 90Glioblastoma 85Lymphoma, Non-Hodgkin 83Colonic Neoplasms 79Squamous Cell Carcinoma of Head and Neck 76Lymphoma, Follicular 76Carcinoma, Renal Cell 75Lymphoma, Large B-Cell, Diffuse 71Hematologic Neoplasms 69Sarcoma 60Stomach Neoplasms 58

Interventions

sonidegib 1devimistat 1PEGPH20 1Gemcitabine 1Albumin-Bound Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Withdrawn × Pancreatic Ductal Adenocarcinoma × Clear all
NCT03374852 2025-04-29

CPI-613 in Combination With Modified FOLFIRINOX in Patients With Locally Advanced Pancreatic Cancer

Thomas Jefferson University

Phase 2 Withdrawn
Gastrointestinal

Pancreatic Ductal Adenocarcinoma

NCT04134468 2020-01-31

MRI Effects of Pegvorhyaluronidase Alfa (PEGPH20) in Pancreatic Ductal Adenocarcinoma

Abramson Cancer Center at Penn Medicine

Phase 2 Withdrawn
Gastrointestinal

Pancreatic Ductal Adenocarcinoma

NCT01911416 2016-06-09

A Biomarker Study to Identify Predictive Signatures of Response to LDE225 (Hedgehog Inhibitor) In Patients With Resectable Pancreatic Cancer

University of Utah

Phase NA Withdrawn
Gastrointestinal

Pancreatic Ductal Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡